prazosin has been researched along with Urethral Obstruction in 16 studies
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.
Urethral Obstruction: Partial or complete blockage in any part of the URETHRA that can lead to difficulty or inability to empty the URINARY BLADDER. It is characterized by an enlarged, often damaged, bladder with frequent urges to void.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to determine if male cats treated with 7 days of prazosin following relief of urethral obstruction (UO) experienced decreased rates of recurrent urethral obstruction (rUO) within 30 days vs those treated with 7 days of placebo." | 9.41 | Effect of prazosin on feline recurrent urethral obstruction. ( Hanson, KR; Linklater, AK; Mochel, JP; Rudloff, E; Yuan, L, 2021) |
| "To determine whether prazosin administration following urethral obstruction (UO) reduces the risk for recurrent urethral obstruction (rUO) or lower urinary tract signs, and to document adverse effects associated with prazosin use in cats." | 9.24 | The effect of prazosin on outcome in feline urethral obstruction. ( Drobatz, KJ; Reineke, EL; Savini, J; Syring, RS; Thomas, EK, 2017) |
| "To determine if prazosin administration decreased the rate of recurrent urethral obstruction (rUO) before hospital discharge and within 14 days." | 8.12 | Prazosin administration increases the rate of recurrent urethral obstruction in cats: 388 cases. ( Conway, DS; Rozanski, EA; Wayne, AS, 2022) |
| "The effects of prazosin HCl on the urethral pressure profile (UPP) were studied in 14 patients with benign prostatic hyperplasia." | 7.68 | Effects of prazosin HCl on the urethral pressure profile in patients with benign prostatic hyperplasia. ( Ishibe, T; Kawashita, E; Nakamura, K; Osumi, Y; Usui, T, 1990) |
| "The aim of this study was to determine if male cats treated with 7 days of prazosin following relief of urethral obstruction (UO) experienced decreased rates of recurrent urethral obstruction (rUO) within 30 days vs those treated with 7 days of placebo." | 5.41 | Effect of prazosin on feline recurrent urethral obstruction. ( Hanson, KR; Linklater, AK; Mochel, JP; Rudloff, E; Yuan, L, 2021) |
| "Prazosin HCl was administered in dosages of 1." | 5.28 | Clinical studies on the effectiveness of prazosin HCl (Minipress tablets) in the treatment of dysuria accompanying benign prostatic hyperplasia. ( Aoki, H; Kobayashi, M; Numazato, S; Ohhori, M; Ohninata, M; Sakuma, S; Shiraiwa, Y; Tsuzuki, T; Yamaguchi, O; Yokota, T, 1990) |
| "To determine whether prazosin administration following urethral obstruction (UO) reduces the risk for recurrent urethral obstruction (rUO) or lower urinary tract signs, and to document adverse effects associated with prazosin use in cats." | 5.24 | The effect of prazosin on outcome in feline urethral obstruction. ( Drobatz, KJ; Reineke, EL; Savini, J; Syring, RS; Thomas, EK, 2017) |
| "Prazosin is well known to most physicians as an effective antihypertensive medication, but its therapeutic value in many cases of benign prostatic hyperplasia (BPH) may be unfamiliar to many." | 5.06 | Clinical overview of prazosin in the treatment of prostatic obstruction. ( Milroy, E, 1990) |
| "Prazosin, a selective alpha 1-adrenoceptor blocker, was compared with Paraprost in a double-blind, multi-institutional study in patients with benign prostatic hyperplasia." | 5.06 | Clinical evaluation of effects of prazosin in patients with benign prostatic obstruction. A double-blind, multi-institutional, Paraprost-controlled study. ( Aoki, H; Kobayashi, M; Ohinata, M; Ohori, M; Shiraiwa, Y; Tsuzuki, T; Yamaguchi, O; Yokota, T, 1990) |
| "Fifty-eight normotensive patients with benign prostatic hyperplasia and maximum urinary flow rates of less than 15 ml/s were randomly assigned to receive a 12-week course of treatment with prazosin or placebo in a double-blind parallel group trial." | 5.06 | A twelve-week placebo-controlled study of prazosin in the treatment of prostatic obstruction. ( Chapple, CR; Christmas, TJ; Milroy, EJ, 1990) |
| "To determine if prazosin administration decreased the rate of recurrent urethral obstruction (rUO) before hospital discharge and within 14 days." | 4.12 | Prazosin administration increases the rate of recurrent urethral obstruction in cats: 388 cases. ( Conway, DS; Rozanski, EA; Wayne, AS, 2022) |
| "Prazosin is a readily available alpha-adrenergic antagonist that may be useful in the management of functional urethral obstruction in companion animals." | 3.72 | Urethral pressure profile and hemodynamic effects of phenoxybenzamine and prazosin in non-sedated male beagle dogs. ( Cribb, AE; Fischer, JR; Lane, IF, 2003) |
| "The effects of prazosin HCl on the urethral pressure profile (UPP) were studied in 14 patients with benign prostatic hyperplasia." | 3.68 | Effects of prazosin HCl on the urethral pressure profile in patients with benign prostatic hyperplasia. ( Ishibe, T; Kawashita, E; Nakamura, K; Osumi, Y; Usui, T, 1990) |
| "No difference in rUO was found in cats treated for urethral obstruction with a 3." | 1.56 | Retrospective evaluation of urinary indwelling catheter type in cats with urethral obstruction (January 2014 to December 2014): 91 cases. ( Davidow, EB, 2020) |
| "Prazosin HCl was administered in dosages of 1." | 1.28 | Clinical studies on the effectiveness of prazosin HCl (Minipress tablets) in the treatment of dysuria accompanying benign prostatic hyperplasia. ( Aoki, H; Kobayashi, M; Numazato, S; Ohhori, M; Ohninata, M; Sakuma, S; Shiraiwa, Y; Tsuzuki, T; Yamaguchi, O; Yokota, T, 1990) |
| "Prazosin HCl was administered to 20 patients with urinary obstructions associated with prostatic hypertrophy." | 1.28 | The efficacy of prazosin HCl in the treatment of urinary flow obstruction due to prostatic hypertrophy. ( Gotoh, M; Ito, K; Kobayashi, M; Kondo, A; Otani, T; Saito, M; Takita, T, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (56.25) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 1 (6.25) | 24.3611 |
| 2020's | 3 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Conway, DS | 1 |
| Rozanski, EA | 1 |
| Wayne, AS | 1 |
| Davidow, EB | 1 |
| Hanson, KR | 1 |
| Rudloff, E | 1 |
| Yuan, L | 1 |
| Mochel, JP | 1 |
| Linklater, AK | 1 |
| Reineke, EL | 1 |
| Thomas, EK | 1 |
| Syring, RS | 1 |
| Savini, J | 1 |
| Drobatz, KJ | 1 |
| Fischer, JR | 1 |
| Lane, IF | 1 |
| Cribb, AE | 1 |
| Velasco, C | 1 |
| Guarneri, L | 1 |
| Leonardi, A | 1 |
| Testa, R | 1 |
| Onur, R | 1 |
| Tasdemir, C | 1 |
| Seckin, D | 1 |
| Ilhan, N | 1 |
| Kutlu, S | 1 |
| Akpolat, N | 1 |
| Straeter-Knowlen, IM | 1 |
| Marks, SL | 1 |
| Rishniw, M | 1 |
| Speth, RC | 1 |
| Wirth, W | 1 |
| Knowlen, GC | 1 |
| Milroy, E | 1 |
| Aoki, H | 2 |
| Ohninata, M | 1 |
| Tsuzuki, T | 2 |
| Ohhori, M | 1 |
| Shiraiwa, Y | 2 |
| Yamaguchi, O | 2 |
| Kobayashi, M | 3 |
| Yokota, T | 2 |
| Numazato, S | 1 |
| Sakuma, S | 1 |
| Kohama, Y | 1 |
| Watanabe, H | 1 |
| Sen, Y | 1 |
| Yamamoto, Y | 1 |
| Morioka, M | 1 |
| Fujita, Y | 1 |
| Nakamura, K | 1 |
| Kawashita, E | 1 |
| Osumi, Y | 1 |
| Usui, T | 1 |
| Ishibe, T | 1 |
| Shimizu, K | 1 |
| Nakai, K | 1 |
| Imai, K | 1 |
| Yamanaka, H | 1 |
| Kondo, A | 1 |
| Gotoh, M | 1 |
| Saito, M | 1 |
| Takita, T | 1 |
| Otani, T | 1 |
| Ito, K | 1 |
| Ohinata, M | 1 |
| Ohori, M | 1 |
| Chapple, CR | 1 |
| Christmas, TJ | 1 |
| Milroy, EJ | 1 |
5 trials available for prazosin and Urethral Obstruction
| Article | Year |
|---|---|
Effect of prazosin on feline recurrent urethral obstruction.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cat Diseases; Cats; Male; Prazosin; Recurrence; Ur | 2021 |
The effect of prazosin on outcome in feline urethral obstruction.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Cat Diseases; Cats; Double-Blind Method; Incidence | 2017 |
Clinical overview of prazosin in the treatment of prostatic obstruction.
Topics: Aged; Clinical Trials as Topic; Humans; Male; Middle Aged; Muscle Contraction; Muscle, Smooth; Prazo | 1990 |
Clinical evaluation of effects of prazosin in patients with benign prostatic obstruction. A double-blind, multi-institutional, Paraprost-controlled study.
Topics: Aged; Aged, 80 and over; Alanine; Double-Blind Method; Drug Combinations; Glutamates; Glycine; Human | 1990 |
A twelve-week placebo-controlled study of prazosin in the treatment of prostatic obstruction.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperpl | 1990 |
11 other studies available for prazosin and Urethral Obstruction
| Article | Year |
|---|---|
Prazosin administration increases the rate of recurrent urethral obstruction in cats: 388 cases.
Topics: Animals; Cat Diseases; Cats; Prazosin; Urethra; Urethral Obstruction | 2022 |
Retrospective evaluation of urinary indwelling catheter type in cats with urethral obstruction (January 2014 to December 2014): 91 cases.
Topics: Animals; Cat Diseases; Catheters, Indwelling; Cats; Male; Prazosin; Recurrence; Retrospective Studie | 2020 |
Urethral pressure profile and hemodynamic effects of phenoxybenzamine and prazosin in non-sedated male beagle dogs.
Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Dog Diseases; Dogs; Heart Rate; Injections, I | 2003 |
Effects of intravenous and infravesical administration of suramin, terazosin and BMY 7378 on bladder instability in conscious rats with bladder outlet obstruction.
Topics: Administration, Intravesical; Adrenergic alpha-Antagonists; Animals; Female; Infusions, Intravenous; | 2003 |
Combined use of melatonin and terazosin restores bladder contractility in rabbits with partial outlet obstruction.
Topics: Adrenergic alpha-Antagonists; Animals; Antioxidants; Drug Therapy, Combination; Humans; Melatonin; M | 2008 |
Urethral pressure response to smooth and skeletal muscle relaxants in anesthetized, adult male cats with naturally acquired urethral obstruction.
Topics: Animals; Cat Diseases; Cats; Dantrolene; Drug Interactions; Male; Muscle, Smooth; Neuromuscular Depo | 1995 |
Clinical studies on the effectiveness of prazosin HCl (Minipress tablets) in the treatment of dysuria accompanying benign prostatic hyperplasia.
Topics: Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Prazosin; Pros | 1990 |
Effects of prazosin HCl on micturition disturbance associated with benign prostatic hypertrophy and bladder neck contracture.
Topics: Humans; Male; Prazosin; Prostatic Hyperplasia; Urethral Obstruction; Urinary Bladder Neck Obstructio | 1990 |
Effects of prazosin HCl on the urethral pressure profile in patients with benign prostatic hyperplasia.
Topics: Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Prazosin; Pres | 1990 |
Effects of an alpha 1-adrenergic blocker (prazosin HCl) on micturition disturbances associated with benign prostatic hypertrophy.
Topics: Aged; Aged, 80 and over; Humans; Male; Middle Aged; Prazosin; Pressure; Prostatic Hyperplasia; Ureth | 1990 |
The efficacy of prazosin HCl in the treatment of urinary flow obstruction due to prostatic hypertrophy.
Topics: Aged; Aged, 80 and over; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Urethral Obstru | 1990 |